Chris is one of tranScrip’s experts in Translational Medicine, Clinical Pharmacology and Early Development having clinical training in Internal Medicine, Nephrology and Clinical Pharmacology. Chris has worked in Early Development for more than 20 years working in The UK, United States and Europe for Pfizer, Amgen and Serono before leading clinical development in Europe for Dainippon Sumitomo Pharma (DSP) before joining tranScrip.
Chris has extensive experience of working with Biopharmaceutics and small molecules targeted across all therapeutic areas with a particular interest in inflammation, neuroscience, biomarker development, cardiovascular disease, nephrology and imaging. Chris also has broad experience of due diligence activities related to in-licensing and out-licensing as well as the application of PK/PD modelling and simulation to early phase development.
Chris was responsible for medical governance, Regulatory Affairs and Pharmacovigilance functions at DSP Europe and has served on Protocol and Ethical review committees for Amgen, Serono and DSP. Whilst at DSP, Chris provided medical support to the development of their commercialisation activities. Chris is a current member of the Faculty of Pharmaceutical Medicine’s Board of Examiners.